Letter by Taegtmeyer and Karlstaedt Regarding Article, “Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)”

Ítems similars

• Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
  per: Kohsaka, Shun, et al.
  Publicat: (2020)
• Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
  per: Kosiborod, Mikhail, et al.
  Publicat: (2017)
• Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering
  per: Neuen, Brendon L., et al.
  Publicat: (2019)
• Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study
  per: Saad, Marwan
  Publicat: (2018)
• Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering
  per: Yanai, Hidekatsu, et al.
  Publicat: (2016)